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Abstract: Hypertension is a major modifiable risk factor for cardiovascular, retinal, and kid-
ney disease. In the past decade, attainment rates of treatment targets for blood pressure control 
in the UK and US have increased; however, ,11% of adult men and women have achieved 
adequate blood pressure control. Technological advances in blood pressure measurement and 
data transmission may improve the capture of information but also alter the relationship between 
the patient and the provider of care. Telemonitoring systems can be used to manage patients 
with hypertension, and have the ability to enable best-practice decisions more consistently. 
The improvement in choice for patients as to where and who manages their hypertension, as 
well as better adherence to treatment, are potential benefits. An evidence base is growing that 
shows that telemonitoring can be more effective than usual care in improving attainment rates 
of goal blood pressure in the short-to-medium term. In addition, studies are in progress to assess 
whether this technology could be a part of the solution to address the health care needs of an 
aging population and improve access for those suffering health inequalities. The variation in 
methods and systems used in these studies make generalizability to the general hypertension 
population difficult. Concerns over the reliability of technology, impact on patient quality of 
life, longer-term utility and cost–benefit analyses all need to be investigated further if wider 
adoption is to occur.
Keywords: telehealth, health surveillance, virtual-led clinic
Introduction
Hypertension is a major, modifiable risk factor for cardiovascular disease (CVD), 
which is a leading cause of mortality in Westernized countries. The American Heart 
Association 2012 update reports mortality rates due to CVD per 100,000 men and 
women aged 35–74 years of 256 and 130 in the US, compared with 202 and 88 in the 
UK, respectively.1 The 2011 Health Survey for England suggests that hypertension 
affects 31% of males and 28% of females over the age of 16, and that every 2 mmHg 
rise in blood pressure (BP) is associated with a 10% and 7% increase in mortality risk 
from ischemic heart disease and cerebrovascular disease, respectively.2 Hypertension 
associated with diabetes is also a leading cause of retinal disease, chronic kidney dis-
ease, and end-stage renal failure in the Western world.3–5 Over the decade up to 2008, 
data from the US National Health and Nutrition Examination Survey showed that the 
prevalence of hypertension remained constant at around 30%, as it did in the UK.2,6
The National Institute for Health and Care Excellence (NICE) in the UK defines 
hypertension in stages. Stage 1 hypertension is a clinic BP $140/90 mmHg and 
subsequent ambulatory BP monitoring (ABPM) daytime average or average home 
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BP monitoring (HBPM) of $135/85 mmHg. Treatment 
is advocated for all affected patients under the age of 
80 years with any target-organ damage, established 
CVD, diabetes, renal disease, or a 10 year cardiovascular 
risk .20%. Patients without target-organ damage should 
be given lifestyle advice and have arrangements made for 
future BP monitoring. Stage 2 hypertension is a clinic BP 
of $160/100 mmHg and subsequent ABPM daytime aver-
age or HBPM $150/95 mmHg. Severe hypertension is a 
clinic systolic BP (SBP) of $180 mmHg and/or diastolic 
BP (DBP) of $110 mmHg, which should be treated regard-
less of age, comorbidities, and cardiovascular risk. Target 
BP is suggested by NICE as ,140/90 in those under the 
age of 80 years, and ,150/90 mmHg for those above the 
age of 80 years.7
A recent study suggests that less stringent BP targets may 
be required in patients with diabetes.8 This opinion is related 
to the so-called J-shaped curve, which indicates that lower 
BP levels may be detrimental in some groups of patients. 
Therefore, especially in the presence of such comorbidities 
as diabetes and renal disease, it is important to be able to 
personalize or tailor treatment to the individual. There is 
a considerable evidence base showing the efficacy of BP-
lowering treatment in reducing the risk of CVD events in 
patients below and above 65 years of age.9 The risk reduc-
tion in stroke and coronary artery disease and delaying the 
progression of renal disease is of the order of 25%–35%.10–12 
Encouragingly, recent data have shown that the proportion of 
patients aware of their hypertension, receiving treatment, and 
reaching goal BP has been increasing over the past decade 
in the US and UK.3,4 There is still a considerable level of 
improvement required for these outcomes. As shown in the 
2011 Health Survey for England, 43.1% of all hypertensive 
patients are currently not receiving medical therapy, and of 
those receiving treatment, 38.1% are inadequately controlled, 
with only 11% of men and 10% of women achieving their 
target BP of ,140/90 mmHg.3
Monitoring blood pressure
The measurement of BP is one of the most common and 
fundamental procedures in medical practice. The pro-
cess has evolved over more than 130 years, and has not 
been immune from the modern revolution in information 
technology.
Von Basch developed the first design for noninvasive 
BP monitoring in approximately 1881. He utilized a water-
filled rubber bulb attached to a mercury manometer and 
determined SBP to be the point at which the arterial pulse 
was obliterated. In 1896, the concept of inflating a cuff 
placed around the arm to generate more uniform pressure 
on the brachial artery was developed by Scipione Riva-
Rocci. Subsequently, clinicians observed the pattern of 
oscillations in the mercury manometers to estimate SBP 
and DBP, and in 1905 Korotkoff introduced auscultatory 
BP measurement.13 The auscultatory technique with the 
mercury sphygmomanometer is the most established method 
of noninvasive BP monitoring, upon which the majority of 
clinical trial outcomes are based.
Alternatives to using the mercury sphygmomanometer 
have been assessed and are considered able to improve 
accessibility of the measurement outside the clinical setting. 
The aneroid meter has a numbered dial, the cuff is manually 
inflated and blood pressure is measured using the ausculta-
tory technique.14 Ma et al compared BP measurements from 
both mercury and aneroid sphygmomanometers and found 
no differences in readings from nearly 1,000 patients across 
24 centers.15 However, the dexterity involved in using the 
aneroid meter and need for regular recalibration limits its 
role in HBPM.
The oscillometric technique overcame the need to detect 
the Korotkoff sounds, and is used in most digital meters. 
In this method, the mean arterial pressure is determined 
and systolic and diastolic blood pressures are deduced 
using preset algorithms. The measurements of these digital 
monitors have been shown to be comparable to invasive and 
noninvasive auscultatory techniques, and because of their 
ease of use and accuracy, they are employed for HBPM and 
ABPM.16
The diagnosis and management of hypertension usually 
takes place in a primary-care setting. There are several 
disadvantages of this approach, including the snapshot BP 
measurement, observer bias, and white-coat effect. Evidence 
has emerged for the role of ABPM and HBPM to identify 
and diagnose hypertension more accurately, and features 
in current guidelines.2 The accuracy and convenience of 
digital measurements has also allowed more BP profiling 
for individual patients. Furthermore, a recent meta-analysis 
suggests that HBPM is more effective but more costly than 
office/clinic BP measurements in achieving target BP.17
The incorporation of telemonitoring with BP mea-
surement via wired and wireless technologies provides a 
method of reducing reporting bias. This sophistication of 
reporting could allow telehealth technologies to dramati-
cally change the relationship between the patient and the 
health care provider in the management of hypertension. 
Therefore, it is necessary to assess the impact of the tech-
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nology itself and the patient’s response to it as part of their 
health management.
Telehealth: changing the delivery 
and impact of health surveillance
Telehealth can be defined as the delivery of health-related 
services over distance using telecommunications. This 
could simply be a telephone conversation between a patient 
and health professional or the more complicated delivery 
of a procedure using robotic technology. Unlike the focus 
on treatment that characterized telemedicine, telehealth 
tries to encompass a more holistic approach to health care 
in the sophistication of the technology to monitor outcomes, 
transmit information, and promote learning that will prevent 
deterioration in health. The advantages of telehealth include 
the assessment of data in real time, and when coupled with 
decision-making strategies can accelerate the delivery of 
best practice.
When compared with specialist health professionals, 
decision-support systems can be more consistent in the 
delivery of clinical decisions that guarantee treatment 
intensification. Our group developed an artificial intelligence 
system written in the PROforma language that contained 
expressions representing clinical criteria to influence and 
plan treatment based on the NICE guidelines to manage 
hypertension.18 Clinic BP data on 219 patients seen either 
in a nurse- (NLC) or a physician-led clinic (PLC) were 
uploaded to a database, which was then subjected to the 
decision system in a virtual setting (VLC). The variables for 
decisions were cardiovascular risk score estimated from the 
Joint British Societies Cardiovascular Risk Assessor, SBP, 
DBP, and use of first-line drugs (FLDs) for managing hyper-
tension. The FLDs were classed as angiotensin-converting 
enzyme inhibitors or receptor blockers, beta-blockers, 
calcium-channel blockers, and thiazide diuretics, which 
were entered according to whether they were prescribed at 
the maximal dose.
Therapeutic decisions were coded as: 1 = monitor only, 
2 = increase FLD, 3 = start a new FLD, or 4 = refer for second-
line agent. Target SBP and DBP were ,130 and ,80 mmHg, 
respectively. The patients seen in the NLC and PLC clinics 
had similar mean (standard deviation) age, SBP, DBP, and 
glycated hemoglobin (63.2 [12.8] versus [vs] 61.6 [13.5] 
years, P = 0.38; 144.9 [19.4] vs 142.2 [12.6] mmHg, P = 0.29; 
77.6 [11.8] vs 78.0 [10.2] mmHg, P = 0.79; and 8.0% [1.8%] 
vs 8.1% [1.5%], P = 0.09). All patients had a CVD score 
of .20%. There were no differences between the groups in 
the prescription of any class of FLD, second-line agent, or 
the proportion on a maximal dose within any class. Decisions 
to monitor only in the PLC group were significantly higher 
and treatment altering decisions 2, 3 and 4 significantly 
lower than in the NLC group (67.6 vs 32.8 and 10.8 vs 35.1, 
13.5 vs 21.6, 8.1 vs 10.4; P = 0.0001). Decisions in VLC 
did not recommend “monitor only,” but suggested decisions 
2 and 3, respectively, for 81% and 19% of the PLC group. 
VLC decisions 1, 2, 3, and 4 were made for 15%, 63%, 19% 
and 3%, respectively, of the NLC group. The kappa estimate 
for agreement with the artificial-intelligence decisions of 
VLC was 0.1 (poor) in the PLC group and 0.3 (fair) for the 
NLC group.19
Therefore, a system using artificial-intelligence system 
algorithms can consistently recognize the impact of CVD 
risk and is more likely to suggest a treatment modification 
than either nurses or physicians in face-to-face consultations 
with the patient. Use of such decision support could possibly 
improve outcomes, and incorporation of such evidence-
based decision-making systems could further develop the 
HBPM potential of telehealth.
The role of telehealth in health care delivery is still being 
actively debated. There are some obvious issues related to the 
adoption of new technology, but what is less easy to assess is 
the impact the interrelationship with care providers and tech-
nology may have on health behavior. Telehealth technology 
has the ability to deconstruct the traditional medical model 
typified in the standard clinical consultation. Although this 
technology has the ability to transfer care closer to home, 
which may ostensibly be better for patients, there is concern 
over its long-term efficacy and impact on quality of life.
The architecture of a typical telehealth system is complex, 
with many links between the components at which problems 
may arise, including authentication, capture, transfer, interpre-
tation, contextualization of data, and provision of an action plan 
(Figure 1). The replacement of the face-to-face, closed, and 
relatively confidential immediate communication in the tradi-
tional medical model is difficult to replicate in telemonitoring. 
A great deal of sophistication and reliability in the hardware 
and software is required to capture patient confidence. More-
over, the health care provider has a crucial role in assessing 
the data (preferably in real time) to maintain the safety of 
the patient. In addition, considerable efforts are necessary to 
ensure that patients’ data remain secure and confidential when 
distributed around such a complex system. The ideal scenario 
in which to deploy these systems will depend on the local 
infrastructure and resources and the patient demographic.
The most important domain in which to devolve care 
is considered to be the home. A number of trials have now 
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Patient station
Bluetooth
connection
4G wireless network
Physician
(specialist)
Bluetooth
connectivity
Case manager
Technician and system
maintenance
Medical
HTTPS
128-bit
Server
Firewall
Control centre
Specialist nurse
Figure 1 Schematic representation of a home (fixed) and smartphone (mobile) telemonitoring systems showing the key relationships between the patient technical and 
medical/nursing health professionals.
Notes: Reproduced by permission of SAGE Publications Ltd., London, Los Angeles, New Delhi, Singapore and Washington DC, from Istepanian RS, Zitouni K, Harry D, 
et al. Evaluation of a mobile phone telemonitoring system for glycaemic control in patients with diabetes. J Telemed Telecare. 15(3):125–128. Copyright © Sage Publications 
Ltd, 2009.35
been published trying to establish the clinical effectiveness 
of HBP telemonitoring (HBPT). However, there is a wide 
range of heterogeneity in the methodology in these trials, 
including variations in the technology of data transmission, 
measuring devices, frequency of monitoring, interface with 
different types of health care professionals to review and 
act on measurements, frequency of patient-to-health care 
provider contact, targets of BP, and duration of study.
Omboni and Guarda carried out a recent meta-analysis 
of 23 randomized controlled trials of HBPT involving 
a total of 7,037 patients.20 Their analysis concluded that 
the HBPT showed a statistically significant improvement 
in SBP and DBP in comparison to usual care. SBP was 
reduced by 4.71 mmHg (95% confidence interval [CI] 
6.18–3.24, P , 0.001) and DBP by 2.45 mmHg (95% CI 
3.33–1.57, P , 0.001). A higher number of prescriptions 
for antihypertensive medications were issued in the HBPT 
group (+0.40, 95% CI 0.17–0.62; P , 0.001), with a greater 
proportion of these patients achieving treatment-target BP 
(relative risk 1.16, 95% CI 1.04–1.29; P , 0.001).
McCant et al investigated the feasibility/technicalities of 
using HBPT in 588 patients with poor BP control random-
ized to three intervention groups (n = 441) using HBPT 
compared with 178 who received usual care.21 Patients in 
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the intervention groups had to transmit their BP and pulse 
readings wirelessly to a home hub, which sent the data via 
the home telephone line to a server. Patients were required 
to check their BP every other day so that there would be a 
total of six readings in a 2-week period. An automated alert 
process was put in place for technical problems and for when 
BP data were not sent according to the protocol. To resolve 
alerts, nurses made contact with the patients and provided 
any necessary intervention materials; the average resolu-
tion time for each alert was 4 days. After 6 months, only 
75% of intervention patients were able to set up monitoring 
and adhere to the study protocol. A total of 693 technical 
alerts were generated by 267 patients, with 61% of all alerts 
being secondary to nonadherence. The 112 patients who 
generated more than two technical alerts were of a younger 
mean age (61 vs 64 years, P , 0.001) and more likely to 
be non-Caucasian (64% vs 47%, P , 0.002) compared to 
those that generated zero to two technical alerts. The device 
or system alerts included failure of the monitor to provide 
readings and problems with the telecommunications hub. 
Of note, the resolution time of the alerts was relatively slow 
and may have impacted patient confidence. Although further 
advances in telecommunications will allow some of these 
difficulties to be overcome, poor patient adherence (and 
confidence) can prove to be a significant limitation to the 
practical use of HBPT. Systems that involve a greater degree 
of patient–health professional interaction may offer greater 
cohesion and trust.
Telehealth and the interface  
between medical and non-medical  
health professionals
The reasons for the limited success in managing BP conven-
tionally are complex. Some of the factors associated with the 
delivery of high-quality care and achievement of treatment 
goals relate to access, appropriateness of the pathway for 
monitoring of BP, patient compliance with treatment, and 
professional attitudes to the implementation and modification 
of treatment. Telemonitoring may have a role in overcoming 
the inertia in acting on BP readings, but itself does not have 
the benefit of the reasoned decision-making a trained physi-
cian has for not adjusting treatment.22 This emphasizes the 
importance of integrating this technology with the decisions 
made by practitioners who take account of the prevailing 
context in which BP was measured.
Pharmacists have been able to improve outcomes in 
hypertension management in the hospital setting, and increas-
ingly are involved with care in the community.23 A systematic 
review of interventions to control BP concluded that systems 
with an organized review of treatment could produce a mean 
reduction in BP of 8.2/4.2 mmHg and reduce all-cause 
mortality.24 Telemonitoring has the potential to link different 
health professionals together and integrate monitoring with 
prescriptive action.
A study by Green et al25 is of particular note with respect 
to the variation in delivering telehealth monitoring and man-
agement of hypertension. In this study of 778 patients, those 
in the active-intervention arms were asked to measure their 
BP with validated home BP monitors twice a week. One 
group worked with their physician, another used additional 
web-based resources to help manage their BP, and a third 
group used the web training plus pharmacist care. The trained 
pharmacist provided assistance with home BP monitoring 
and web communications via planned telecommunication. 
At the end of the trial, the proportion of patients achieving 
controlled BP (,140/90 mmHg) was similar in those who 
received web training only compared with usual care (36% 
[95% CI 30%–42%] vs 31% [95% CI 25%–37%]; P = 0.21). 
However, pharmacist-assisted, web-based HBPM signifi-
cantly increased the percentage of patients with controlled 
BP (56%, 95% CI 49%–62%) compared with usual care 
(P , 0.001) and home BP monitoring and web training only 
(P , 0.001).25 In this population, the added interaction with 
a health care provider improved BP outcomes particularly in 
the group with higher BP, who were at greater risk of CVD. 
This study suggests that pharmacists have a key role in blood 
pressure management at the interface between the patient and 
technical advances in BP measurement.
The patient–technology interface
The Rosenstock health-belief model suggests that perceived 
seriousness of, and susceptibility to a condition with cues to 
action will improve an individual’s readiness to change health 
behaviors or take up a health service.26 A key issue regarding 
the improved ability to monitor BP in different environments 
is to standardize the process to act on the outcome data and 
change medication and/or monitoring. In the Telemonitor-
ing and Self-Management in the Control of Hypertension 
(TASMINH2) trial, 527 patients were randomized to usual 
care (n = 264) or HBPT with self-care (n = 263). Those in 
the intervention group were given preset instructions for two 
antihypertensive modifications they could make themselves if 
they had concerning BP readings on a number of occasions. 
At the end of the study, 80% of patients had completed the 
12-month protocol, and data from 91% were included in 
the final analysis. There was a significantly greater fall in 
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mean SBP in the HBPT/self-care group compared to those 
in the usual care group at 6 and 12 months (3.7 mmHg, 95% 
CI 0.8–6.6; P = 0.013) and 5.4 mmHg (95% CI 2.4–8.5, 
P = 0.0004), respectively.27 The study by Green et al25 and 
the TASMINH2 trial27 emphasizes the importance of patient 
education, self-monitoring, and support for acting on advice 
provided with HBPT interventions. Therefore, in select 
groups, addressing the three concepts of Rosenstock et al’s 
model could possibly improve the management of hyperten-
sion with telemonitoring.
Wireless communication such as Bluetooth technology 
may improve the patient experience with telemonitoring. It is 
more flexible than home-based systems, and approaches the 
ideal of delivering health monitoring for the patient anytime 
and anywhere in real time. Logan et al utilized HBPT using 
a validated, Bluetooth-enabled home BP device paired with 
a smartphone that ran an application that transmitted every 
reading to an application server. The data were then processed 
with decision rules, and an automated self-care message was 
generated and sent to the patient’s smartphone following 
every reading. Examples of messages included reassurance 
that BP control was satisfactory, advice regarding the need 
for changes in the frequency of monitoring, or arranging 
follow-up with a health care professional. Nonadherence 
also triggered an automated voice message that was sent 
to the patient’s phone line. In this study, 110 patients with 
uncontrolled systolic hypertension (and diabetes) were ran-
domly allocated to either HBPT intervention and self-care 
support (n = 55) or usual care (n = 55). After 1 year, there 
was a significant decrease observed in the mean (standard 
deviation) daytime SBP within the intervention group of 
9.1 (15.6) mmHg (P , 0.0001), as well as between groups 
of 7.1 (2.3) mmHg (P , 0.005). Treatment-target BPs were 
also achieved in a greater proportion of patients in the inter-
vention than in the control group (51% vs 31%, P , 0.05). 
No significant change in BP was noted within the control 
group itself over the 12-month period.28 The improvement 
in BP in this study was independent of changes to antihy-
pertensive medications or visits to physicians. In contrast, 
in the TASMINH2 study, 148 patients made at least one 
medication change and in the intervention group 0.46 (95% 
CI 0.34–0.58) additional antihypertensive agents were used 
compared to the control group (P = 0.001). This difference 
was related to the difference in methodology, but together it 
shows that improvement in patient behaviors per se can bring 
about significant improvements in BP outcomes that can be 
facilitated by an appropriate telemonitoring system that also 
encourages self-care.
Patients may feel more isolated and become burdened 
by the process and responsibility of making, transmitting, 
and acting on these BP measurements. It has been suggested 
that telehealth may be potentially harmful and increase 
depression and anxiety. However, in a nested study in 1,573 
patients with chronic pulmonary disease, heart failure, and 
diabetes, there were no statistically significant differences 
in anxiety and depression scores after 12 months in the 
telehealth group compared to those receiving usual care.29 
In contrast, in the study by Green et al, those who had inter-
action with the health professional had better qualitative 
outcomes.25 In a meta-analysis of randomized control trials 
where quality of life could be assessed, it was found that 
physical health scores were significantly higher in HBPT 
(+2.78, 95% CI 1.15–4.41; P , 0.001), and there was no 
significant difference in mental health scores.20 A recent 
HBPT study comparing self-care and usual care alone found 
no significant differences in the anxiety component of the 
Hospital Anxiety and Depression Scale; however, within 
the intervention group there was a higher depression score 
at 12 months compared to their baseline.28 Although these 
data suggest telehealth does no harm, further qualitative 
analyses are required. In addition, these qualitative outcomes 
should be assessed when deploying telehealth interventions 
in groups with or at high risk of anxiety and depression, such 
as those with multiple comorbidities.
The clinical benefits of managing hypertension effectively 
in patients with other comorbidities complicating hyperten-
sion, such as diabetes, is well established.30 However, data 
on the utility and efficacy of telemonitoring in populations 
at very high risk of CVD are limited. Our group performed 
the first randomized, controlled trial in patients with type 2 
diabetes who were characterized by being at risk of progres-
sive renal dysfunction. Both blood glucose and blood pressure 
and Bluetooth-enabled sensors were used together to transmit 
data to smartphones. We studied 137 patients who were ran-
domized to either mobile telemonitoring (n = 72) or usual 
care (n = 65). Clinic BP was recorded at baseline and after 
6 months. Patients in the intervention arm transmitted weekly 
to clinicians, who received the data in real time, and using a 
web-based application provided management advice to the 
patient and their physicians. In an intention-to-treat analysis, 
the study SBP fell significantly in patients in the interven-
tion group (mean [95% CI] −6.5 [−0.8 to −12.2] mmHg, 
P = 0.027) and remained unchanged in the control group (2.1 
[9.3 to −5.0] mmHg, P = 0.57). Patients of African origin 
within the intervention arm seemed to benefit more from 
the intervention. In addition, those who achieved an SBP 
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of ,120 mmHg had lower average blood sugars than those 
with higher readings.31
In the Informatics for Diabetes Education and Tele-
medicine (IDEATel) study,32 1,665 middle-aged Medicare 
recipients with diabetes were randomized to usual care or 
an intervention with a home telemedicine unit used for 
web access, videoconferencing with a health care profes-
sional and monitoring of glucose and BP. After 12 months, 
SBP and DBP were respectively lower in the intervention 
group (3.4 mmHg [P = 0.001] and 1.9 mmHg [P , 0.001]). 
Therefore, telehealth systems may benefit disadvantaged 
groups because of systematic health inequalities and ethnic 
or environmental factors that increase the susceptibility to 
poor disease outcomes. In this respect, the results of the 
ongoing study by Egede et al will be of interest. This group 
has planned a 4-year prospective, randomized clinical trial, 
which will test the effectiveness of technology-assisted case 
management in low-income rural adults with type 2 diabetes. 
Two hundred male and female participants, 18 years of age 
or older and with poor diabetes control will be randomized 
into the intervention arm using the FORA system – home-
based telemonitoring using cable data transfer – coupled 
with nurse case management or usual care.33 The forthcom-
ing Blood Pressure Control and Compliance to Treatment 
in  Hypertensive Patients with Metabolic Syndrome: a 
Study Based on Home Blood Pressure Telemonitoring and 
Assessment of Psychological Determinants (TELEBPMET) 
trial aims to investigate HBPT vs usual care in patients with 
metabolic syndrome, where telehealth may have an appli-
cation in patients who are at risk of developing CVD and 
 diabetes. In addition to the primary outcome of the proportion 
of patients achieving adequate BP control at 24 and 48 weeks, 
it will assess secondary outcomes, including a cost–benefit 
analysis and psychological determinants of adherence and 
compliance with drug therapy.34
Future considerations  
for telehealth in hypertension
In the last decade, an increasing number of studies have 
shown supportive evidence for the use of telehealth in 
patients with hypertension and other comorbidities. A struc-
tured monitoring pathway (short- versus longer-term) as 
opposed to the unspecified intention of the studies to date 
will help to answer questions of how best to deploy this tech-
nologically and use telehealth possibly in a more strategic 
fashion. For example, when a patient achieves target BP, they 
could/should be encouraged to adhere to lifestyle changes 
and therapies to maintain this, rather than focusing on the 
monitoring process. Further, monitoring could be used on 
an interim basis for specific clinical or therapeutic reasons 
in certain groups.
There are concerns that we have cited in this review that 
suggest the change in responsibility for measurement and 
isolation from face-to-face professional support might have 
a negative impact on the patient’s quality of life. There are 
very little data on the costs versus benefits of this technology 
and how it relates to the patient’s quality of life, which can 
be addressed with more studies using mixed (quantitative 
and qualitative) method designs. The monitoring period per 
se could be investigated as a management utility, and the 
type of system (fixed, mobile, wireless) or technology for 
a specific clinical requirement that also meets the patient’s 
needs requires further evaluation. HBPT with self-care ver-
sus HBPT with health care professional support needs to be 
evaluated in a head-to-head, sufficiently powered, randomized 
controlled study. These studies are important for the develop-
ment and future adoption of this technology.
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